Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any issues are welcome. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment options (if involved); it does not constitute any investment advice.
May 7,Nanjing, China,Nanjing Bioheng Biotech Co., Ltd.(Nanjing Bioheng Biotech Co., Ltd.), an innovative biopharmaceutical company focused on the development and commercialization of universal immune therapy (UCAR-T) products, announced today that it will present the Phase I clinical data of its universal CAR-T cell product RD13-02 targeting CD7 for the treatment of R/R T-ALL/LBL patients in the form of an academic poster at the 29th European Hematology Association Annual Meeting (EHA 2024), to be held from June 13-16, 2024, in Madrid, Spain.
About RD13-02
RD13-02 is a universal CAR-T cell product derived from healthy donors, targeting CD7, used for treating relapsed/refractory CD7-positive T-cell acute lymphoblastic leukemia/lymphoma. It avoids fratricide through genetic modification.Graft-versus-host disease(GvHD) and host versus graft rejection (HvG), while enhancing anti-tumor activity. RD13-02 can be prepared in a single batch for multiple uses, achieving the goal of "ready-to-use" when patients require CAR-T cell therapy.
Nanjing Bioheng Biotech Co., Ltd. is a clinical-stage company focused on the development and clinical translation of allogeneic "off-the-shelf" universal CAR-T therapies. Established in 2017, the company aims to develop world-leading integrated cell therapy platforms and products to address the most challenging and unmet medical needs.In March 2022, Nanjing Bioheng Biotech Co., Ltd.'s CTA101 product received the first Investigational New Drug (IND) approval in China for an allogeneic CAR-T cell therapy.In June 2021, Bioheng Biotech Co., Ltd. targetedCD7 TargetThe universal CAR-T cell therapy has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL). This product is based on Bioheng Biotech's proprietary universal CAR-T technology platform — ANSWER®. The company is advancing global clinical trials for this promising product pipeline.Based on the ANSWER® platform, Nanjing Bioheng Biotech Co., Ltd. is actively developing multiple universal CAR-T product pipelines. These projects have demonstrated strong and persistent allogeneic CAR-T cell survival capabilities, showing great potential in the fields of autoimmunity and oncology.
Source of the article:Bioheng Biotech
